Glycine transporter type-1 and its inhibitors

L. Hársing, Z. Juranyi, I. Gacsalyi, P. Tapolcsányi, A. Czompa, P. Mátyus

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The ionotropic glutamate receptor NMDA is allosterically modulated by glycine, a coagonist, its presence is an absolute requirement for receptor activation. The transport of glycine in glutamatergic synapse is carried out by glycine transporter-1 (GlyT1), a Na+/Cl--dependent carrier molecule. The primary role of GlyT1 is to maintain glycine concentrations below saturation level at postsynaptic NMDA receptors. Several isoforms of GlyT1 (a-e) have been identified, which are expressed both in glial and neuronal cell membranes. GlyT1 operates bidirectionally: it decreases synaptic glycine concentration when operates in normal mode and releases glycine from glial cells as operates in a reverse mode. It is expected that non-transportable, non-competitive inhibitors of GlyT1 may have therapeutic value in CNS disorders characterized by hypofunctional NMDA receptor-mediated glutamatergic neurotransmission. Accordingly, GlyT1 inhibitors exhibited antipsychotic profile in a number of animal tests. The first promising in vitro and in vivo experiments with glycine itself, and its N-methyl analogue, sarcosine, had initiated the syntheses of potential GlyT1 inhibitors with more complex structures, in which, however, the glycine or sarcosine moiety had always been incorporated. Those attempts led to the development of two compounds, ALX-5407 and Org-24461 with high inhibitory potency; however, none of which is now considered as a drug candidate due, most probably, to safety and/or pharmacokinetic issues. More recently, several structurally new series of highly potent inhibitors with no aminomethylcarboxy group have also been discovered. Some of them might be expected to fulfill all requirements for clinical development. The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions.

Original languageEnglish
Pages (from-to)1017-1044
Number of pages28
JournalCurrent Medicinal Chemistry
Volume13
Issue number9
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Glycine Plasma Membrane Transport Proteins
Glycine
Sarcosine
N-Methyl-D-Aspartate Receptors
Neuroglia
Ionotropic Glutamate Receptors
Pharmacokinetics
N-Methylaspartate
Cell membranes
Synaptic Transmission
Synapses
Antipsychotic Agents
Schizophrenia
Protein Isoforms
Animals
Chemical activation
Cell Membrane
Safety

Keywords

  • Astroglia cell
  • Glycine
  • Glycine transporter inhibitors
  • Glycine transporters
  • Glycine uptake
  • NFPS
  • NMDA receptor
  • Org-24461
  • Sarcosine
  • Schizophrenia

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Glycine transporter type-1 and its inhibitors. / Hársing, L.; Juranyi, Z.; Gacsalyi, I.; Tapolcsányi, P.; Czompa, A.; Mátyus, P.

In: Current Medicinal Chemistry, Vol. 13, No. 9, 04.2006, p. 1017-1044.

Research output: Contribution to journalArticle

Hársing, L. ; Juranyi, Z. ; Gacsalyi, I. ; Tapolcsányi, P. ; Czompa, A. ; Mátyus, P. / Glycine transporter type-1 and its inhibitors. In: Current Medicinal Chemistry. 2006 ; Vol. 13, No. 9. pp. 1017-1044.
@article{a86dd032fd254a71bbcae5be2931ab2d,
title = "Glycine transporter type-1 and its inhibitors",
abstract = "The ionotropic glutamate receptor NMDA is allosterically modulated by glycine, a coagonist, its presence is an absolute requirement for receptor activation. The transport of glycine in glutamatergic synapse is carried out by glycine transporter-1 (GlyT1), a Na+/Cl--dependent carrier molecule. The primary role of GlyT1 is to maintain glycine concentrations below saturation level at postsynaptic NMDA receptors. Several isoforms of GlyT1 (a-e) have been identified, which are expressed both in glial and neuronal cell membranes. GlyT1 operates bidirectionally: it decreases synaptic glycine concentration when operates in normal mode and releases glycine from glial cells as operates in a reverse mode. It is expected that non-transportable, non-competitive inhibitors of GlyT1 may have therapeutic value in CNS disorders characterized by hypofunctional NMDA receptor-mediated glutamatergic neurotransmission. Accordingly, GlyT1 inhibitors exhibited antipsychotic profile in a number of animal tests. The first promising in vitro and in vivo experiments with glycine itself, and its N-methyl analogue, sarcosine, had initiated the syntheses of potential GlyT1 inhibitors with more complex structures, in which, however, the glycine or sarcosine moiety had always been incorporated. Those attempts led to the development of two compounds, ALX-5407 and Org-24461 with high inhibitory potency; however, none of which is now considered as a drug candidate due, most probably, to safety and/or pharmacokinetic issues. More recently, several structurally new series of highly potent inhibitors with no aminomethylcarboxy group have also been discovered. Some of them might be expected to fulfill all requirements for clinical development. The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions.",
keywords = "Astroglia cell, Glycine, Glycine transporter inhibitors, Glycine transporters, Glycine uptake, NFPS, NMDA receptor, Org-24461, Sarcosine, Schizophrenia",
author = "L. H{\'a}rsing and Z. Juranyi and I. Gacsalyi and P. Tapolcs{\'a}nyi and A. Czompa and P. M{\'a}tyus",
year = "2006",
month = "4",
doi = "10.2174/092986706776360932",
language = "English",
volume = "13",
pages = "1017--1044",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Glycine transporter type-1 and its inhibitors

AU - Hársing, L.

AU - Juranyi, Z.

AU - Gacsalyi, I.

AU - Tapolcsányi, P.

AU - Czompa, A.

AU - Mátyus, P.

PY - 2006/4

Y1 - 2006/4

N2 - The ionotropic glutamate receptor NMDA is allosterically modulated by glycine, a coagonist, its presence is an absolute requirement for receptor activation. The transport of glycine in glutamatergic synapse is carried out by glycine transporter-1 (GlyT1), a Na+/Cl--dependent carrier molecule. The primary role of GlyT1 is to maintain glycine concentrations below saturation level at postsynaptic NMDA receptors. Several isoforms of GlyT1 (a-e) have been identified, which are expressed both in glial and neuronal cell membranes. GlyT1 operates bidirectionally: it decreases synaptic glycine concentration when operates in normal mode and releases glycine from glial cells as operates in a reverse mode. It is expected that non-transportable, non-competitive inhibitors of GlyT1 may have therapeutic value in CNS disorders characterized by hypofunctional NMDA receptor-mediated glutamatergic neurotransmission. Accordingly, GlyT1 inhibitors exhibited antipsychotic profile in a number of animal tests. The first promising in vitro and in vivo experiments with glycine itself, and its N-methyl analogue, sarcosine, had initiated the syntheses of potential GlyT1 inhibitors with more complex structures, in which, however, the glycine or sarcosine moiety had always been incorporated. Those attempts led to the development of two compounds, ALX-5407 and Org-24461 with high inhibitory potency; however, none of which is now considered as a drug candidate due, most probably, to safety and/or pharmacokinetic issues. More recently, several structurally new series of highly potent inhibitors with no aminomethylcarboxy group have also been discovered. Some of them might be expected to fulfill all requirements for clinical development. The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions.

AB - The ionotropic glutamate receptor NMDA is allosterically modulated by glycine, a coagonist, its presence is an absolute requirement for receptor activation. The transport of glycine in glutamatergic synapse is carried out by glycine transporter-1 (GlyT1), a Na+/Cl--dependent carrier molecule. The primary role of GlyT1 is to maintain glycine concentrations below saturation level at postsynaptic NMDA receptors. Several isoforms of GlyT1 (a-e) have been identified, which are expressed both in glial and neuronal cell membranes. GlyT1 operates bidirectionally: it decreases synaptic glycine concentration when operates in normal mode and releases glycine from glial cells as operates in a reverse mode. It is expected that non-transportable, non-competitive inhibitors of GlyT1 may have therapeutic value in CNS disorders characterized by hypofunctional NMDA receptor-mediated glutamatergic neurotransmission. Accordingly, GlyT1 inhibitors exhibited antipsychotic profile in a number of animal tests. The first promising in vitro and in vivo experiments with glycine itself, and its N-methyl analogue, sarcosine, had initiated the syntheses of potential GlyT1 inhibitors with more complex structures, in which, however, the glycine or sarcosine moiety had always been incorporated. Those attempts led to the development of two compounds, ALX-5407 and Org-24461 with high inhibitory potency; however, none of which is now considered as a drug candidate due, most probably, to safety and/or pharmacokinetic issues. More recently, several structurally new series of highly potent inhibitors with no aminomethylcarboxy group have also been discovered. Some of them might be expected to fulfill all requirements for clinical development. The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions.

KW - Astroglia cell

KW - Glycine

KW - Glycine transporter inhibitors

KW - Glycine transporters

KW - Glycine uptake

KW - NFPS

KW - NMDA receptor

KW - Org-24461

KW - Sarcosine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33646005519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646005519&partnerID=8YFLogxK

U2 - 10.2174/092986706776360932

DO - 10.2174/092986706776360932

M3 - Article

C2 - 16611082

AN - SCOPUS:33646005519

VL - 13

SP - 1017

EP - 1044

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 9

ER -